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Early transient presence of implanted bone marrow stem cells reduces lesion size after cerebral
ischaemia in adult rats
Aims:Previous studies on the therapeutic time window for
intravascular administration of bone marrow stem cells
(BMSCs) after stroke have shown that early intervention
(from 3 h after onset) in the middle cerebral artery occlu-
sion (MCAO) rat model is the most effective approach
to reduce ischaemic lesion size. We have confirmed these
observations but noticed that 2 weeks after transplanta-
tion, almost none of the grafted BMSCs could be detected
in or around the lesion. The present experiments aimed to
assess the fate and kinetics of intravascularly injected
BMSCs shortly after administration in correlation to
the development of the ischaemic lesion after MCAO.
Methods: We administered a syngeneic suspension of
complete (haematopoietic and mesenchymal) BMSCs via
the carotid artery to rats at 2 h after MCAO onset. We
examined the distribution and tissue location of BMSCs
within the first 24 h after arterial administration by
perfusion-fixating rats and performing immunohis-
tochemical analysis at different time points. Results:
The vast majority (>95%) of BMSCs appeared to become
trapped in the spleen shortly after injection. Six hours
after implantation, together with the appearance of acti-
vated microglia, the first BMSCs could be detected in and
around the lesion; their number gradually increased
during the first 12 h after implantation but started to
decrease at 24 h. The implanted BMSCs were surrounded
by activated and phagocytotic microglia. Conclusion: Our
results show that ischaemic lesion size reduction can
already be achieved by the early transient presence at the
lesion site of intravascularly implanted BMSCs, possibly
mediated via activated microglia.
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Introduction
Ischaemic stroke is one of the neurological disorders that
has been examined in experimental animals as a potential
target for stem cell therapy to enhance long-term stroke
recovery as a more promising alternative to largely unsuc-
cessful drug approaches [1,2]. In view of the claimed
pluripotency of both haematopoietic and mesenchymal
bone marrow stem cells (BMSCs), their ability to cross the
blood–brain barrier and their relatively easy autologous
accessibility, these cells have been considered as promi-
nent candidate stem cells. Intracerebral, intravenous or
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intra-arterial administration of BMSCs starting from 24 h
after transient middle cerebral artery occlusion (MCAO)
has been demonstrated to improve the functional outcome
in this experimental ischaemic stroke model (for reviews
[3–7]). Even delayed treatment at 7 days or even at 1
month after stroke onset was reported to increase brain
plasticity and to improve long-term functional outcome.
The mechanism of the neurorestorative effect of BMSCs
initially has been merely ascribed to their claimed pluripo-
tency and their ability to differentiate into brain cell lin-
eages, and so replacing lost astrocytes, oligodendrocytes,
neurons and endothelial cells. However, the number of
implanted BMSCs and their derivatives recovered at the
lesion site appeared to be highly variable, and was in most
cases not correlated to the extent of the beneficial effects.
Instead, growing evidence suggests that the secretory
products of BMSCs may be the active agents. BMSCs
secrete a wide variety of growth factors (e.g. VEGF, bFGF
and BDNF) that support angiogenesis, neurogenesis and
synaptic plasticity, and by doing so promote the functional
outcome [8–11]. In general, however, despite an improve-
ment in functional readout parameters, the core of the
ischaemic lesion appeared hardly reduced in size after
these non-acute injections of BMSCs; an increased rescue
and protection of neurons in the penumbra region and an
increased synaptic plasticity seemed to account for the
functional improvement observed after stroke.
A study on the therapeutic time window for acute intra-
vascular administration of BMSCs by Iihoshi et al. [12],
however, showed that very early intervention in the MCAO
model in the rat (that is, ranging from 3 to 12 h after
stroke onset) indeed can reduce the actual lesion size.
Infusion of BMSCs as early as 3 h after a MCAO of 45 min
almost completely abolished the lesion with only some
inflammatory responses visible [12]. Two weeks after
transplantation, Iihoshi et al. found that BMSCs had accu-
mulated in and around the site of the ischaemic lesion,
with some of them expressing neuronal and astrocytic
markers [12], although the actual percentages and the
significance level remained unclear. The optimal 3 h time
frame described in their experimental study may be of
clinical interest, as it coincides with the time window
given to stroke patients for acute successful intra-arterial
thrombolysis [13]. The present experiment was designed
to assess the fate and kinetics of intravascularly injected
BMSCs shortly after administration in correlation to the
development of the ischaemic lesion after MCAO, includ-
ing neuronal degeneration and microglia response.
Materials and methods
Animals
In total, 65 male inbred Wistar rats (Charles-River
Laboratories, Wilmington, MA, USA) with a bodyweight
ranging between 350–400 g were used. The rats had free
access to water and food before and after the procedures.
All animal experiments were carried out in accordance
with the National Institute of Health Guide for the Care
and Use of Laboratory Animals and with regulations of
the local Experimental Animal Committee.
BMSC preparation
For the preparation of BMSC suspensions, a littermate
of the recipient rat was quickly terminated by cervical
dislocation under halothane anaesthesia. The femur was
rapidly dissected and completely cleaned from adherent
tissue. After removing the knee joint, a needle connected
to a 1 ml syringe, with 1 ml of basic alpha medium (Invit-
rogen, Breda, The Netherlands) plus 5% FCS (foetal calf
serum), was inserted through the knee plane into the
femur. Both the needle and the femur were placed in a
5 ml tube and the medium was firmly injected into the
femur and vigorously flushed two times. Subsequently, the
cell suspension was mechanically disassociated by re-
peatedly flushing the suspension through the needle. The
cells were then placed on ice and erythrocytes were lysed
with erythrocyte lysis buffer (8.26 g NH4Cl, 1 g NH4HC03,
0.0037 g EDTA in 1 l of aqua dest), 3 ml per 50 million
cells, during 10 min. Cells were washed three times in
PBS + 0.2% BSA and in PBS, counted and re-suspended
(107/ml) in basic alpha medium plus 5% FCS. Cells were
incubated overnight at 37°C in this medium in order to
remove T cells and monocytes and to label the cells with a
rhodamine–dextran conjugate (‘mini-Ruby’; 20 mg/ml).
Next day, the cells were washed and counted for a final
concentration of 107 cells/100 ml in saline. This proce-
dure yielded a pure CD34/CD45-positive mononuclear
BMSC fraction, with a rhodamine–dextran labelling
efficiency of over 98%.
Focal cerebral ischaemia Rats were anaesthetized with a
nitrous oxide/oxygen/halothane mixture (69%/30%/1%)
administered through an inhalation mask. During the
whole procedure, rats were kept on a temperature of 37°C
by placing them on a heating pad. MCAO was induced by
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the intraluminal filament technique [14]. In brief, the left
carotid bifurcation was exposed, and the external carotid
artery (ECA) was coagulated distal to the bifurcation.
Close to the bifurcation, a ligature was loosely tied around
the ECA. A 40-mm 3-0 nylon monofilament (Rico, Debre-
cen, Hungary) with a heat-blunted spherical tip was
inserted through a small opening in the stump of the ECA
and gently advanced (approximately 20 mm) through the
internal carotid artery (ICA) until it blocked the middle
cerebral artery. After 1 h of occlusion, the intraluminal
monofilament was gently withdrawn, the ligature around
the ECA was tightened, reperfusion was restored and the
wound was closed temporarily to enable BMSC adminis-
tration via the ECA after 1 h of reperfusion.
Intra-arterial administration of BMSCs After 1 h, the
wound was re-opened, clips were placed on the ICA and the
common carotid artery and, along the ligature, a blunt
needle connected to a catheter was inserted into the ECA.
The catheter was filled with saline to prevent air bubbles
and was connected to a syringe filled with labelled stem
cells. The ligature around the ECA was tightened around
the blunt needle and the clip on the ICA was removed. The
connection was tested by gently retrieving some blood from
the ECA.Then, 100 ml of saline containing 1 000 000 cells
(in control groups just saline) was slowly injected through
the blunt needle. After injection, the clip was placed back
onto the ICA and the blunt needle was extracted from the
ECA.The ECA was coagulated below the opening to prevent
bleeding. The clips were removed to reperfuse the brain and
the incision was cleaned and closed.
Perfusion fixation At various time points after MCAO and
BMSC administration, rats were anaesthetized with pen-
tobarbital and intracardially perfused with approximately
250–300 ml of 4% paraformaldehyde in 0.1 M PBS
(pH = 7.4). The complete brain, including cerebellum, was
excised and post-fixed in 4% paraformaldehyde for 48 h,
then changed to 0.1 M PBS containing 0.1% azide.
Samples from liver, lung and spleen were also collected in
order to analyse the presence of transplanted BM stem
cells in these organs.
Immunohistochemistry For immunohistochemical analy-
sis of the BMSC-treated stroke-induced brain lesions,
14-mm-thick coronal sections were cut on a cryostat
microtome (Leica, Rijswijk, the Netherlands). Sections
were collected on gelatine/poly-L-lysine-coated glass slides
starting from Bregma -1.6 mm [15], that is, at the level
that the left–right connection of the corpus callosum was
visible, throughout the striatum up to Bregma 2.4 mm.
Random 14-mm-thick sections were cut from the liver,
spleen and lung specimens.
In order to optimize the exposure of, in particular,
nuclear antigens to the primary and secondary antibodies
during the immunohistochemical staining procedure, a
number of sections were subjected to an antigen retrieval
method. Glass slides with sections were placed in a cuvet
containing 10 mM sodium citrate and heated in a micro-
wave for 5 min on 20% capacity. After cooling the cuvet at
room temperature for 5 min, the sodium citrate was
removed and replaced by ice-cold 0.1 M PBS for 5 min.
Besides a histochemical overview staining with cresyl-
violet, we have analysed the size and the cellular compo-
sition of the ischaemic lesion in the striatum and the
consequences of BM stem cell treatment with various
primary antibodies in immunohistochemical procedures.
We identified dying neurons in the core of the lesion with
anti-activated caspase-3 and still viable neurons in the
penumbra with anti-NeuN. The penumbra contains
neurons that have been injured but might still have the
capacity for regeneration; re-outgrowth of their neurites
was detected using anti-GAP43, a growth-associated
protein. Degenerating cells in the lesion recruit/attract
microglia, which we identified by using anti-Iba-1 (ionized
calcium binding adapter 1, Wako Chemicals GmbH,
Neuss, Germany). The implanted BMSCs were labelled
with a red fluorescent rhodamine–dextran conjugate
(mini-Ruby, see above), which enables their detection in
the brain sections. Additionally, we have used anti-CD34
and anti-CD45 to confirm the identity of the red-
fluorescent, grafted BM stem cells. In order to detect
grafted BMSCs that might have differentiated into a neural
cell type, we have examined the co-labelling of mini-Ruby
with immunostaining after incubation with anti-MAP2
(neuron), anti-GFAP (astrocyte) and anti-RIP (oligoden-
drocyte). Although most immunoreactivity was detected
with fluorescence using proper, fluorescently labelled sec-
ondary antibodies, in some instances peroxidase-mediated
diamino-benzidine staining was performed. In these cases,
endogenous peroxidase was blocked in a pre-treatment
with 0.3% H2O2 in PBS during 30 min.
(Immuno-)histometrical analysis Immunofluorescent
sections were analysed under a Leica (SP2 AOBS) Con-
focal Laser Scan Microscope and a Zeiss (Axioskope 2)
Bone marrow stem cells after stroke 91












Figure 1. Ischaemic lesion in striatum 2 weeks after middle cerebral artery occlusion. A schematic drawing of brain section shows the
striatal areas depicted in a–d. (a,a’) Iba-1 immunostaining (brown) for activated microglia clearly delineates the lesion in the left side of the
striatum; magnification of indicated area in a’. (b,b’) In contrast, the contralateral unaffected side of the striatum only shows a homogenous
distribution of quiescent microglia; magnification of indicated area in b’. (c,c’) Immunostaining with anti-NeuN (brown), which labels nuclei
of viable neurons, shows the degeneration of neurons in the ischaemic striatal lesion; magnification of indicated area in c’. (d,d’) In the
contralateral striatum, NeuN-labelled neurons lay distributed throughout the unaffected striatum; magnification of indicated area in d’ (cor,
cortex; cc, corpus callosum; str, striatum). Bars in a–d, 1 mm; in a’–d’, 0.1 mm.
92 E. Keimpema et al.
© 2009 Blackwell Publishing Ltd, Neuropathology and Applied Neurobiology, 35, 89–102
Fluorescent Microscope. The size of the ischaemic lesion
was measured with a Quantimet system (Leica). For this
purpose, every 5th Iba-1-stained coronary brain section
(14 mm) was captured on a computer screen. After manu-
ally outlining the clear edges of the darkly Iba-1-stained
lesion, the Quantimet software calculated the size of the
lesion. The total infarct volume was calculated by summa-
tion of the infarcted area of all brain sections, including the
interpolated area of the four intermediate sections. For cell
counting of stained brain sections captured on a computer
screen, Image J software (NIH Image, Bethesda, MD, USA)
was used. Data were analysed and plotted in Microsoft
Excel (Microsoft Corporation, Redmond, WA, USA).
Statistical analysis Statistical tests were performed in
Statistica 7.0 (Statsoft, Inc., Tulsa, OK, USA). All data were
rank-transformed, because the data were not normally
distributed. The course of the data was examined with an
analysis of covariance. Differences between groups were
analysed using a post hoc Turkey pair-wise comparison.
Significant differences were accepted for P < 0.05.
Results
Ischaemic lesion after 2 weeks
Two weeks after MCAO of 1 h, brain sections showed
a bean-shaped area of degenerated neurons revealed by
the anti-NeuN neuronal nuclear immunostaining
(Figure 1c,d). In the core of the lesion, no NeuN-positive
viable neurons were detectable. In reaction to the tissue
degeneration, activated Iba-1-positive microglia had
invaded the entire ischaemic lesion area (Figure 1a,b). At
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to discriminate anymore between the core and the penum-
bra of the ischaemic lesion. The ischaemic lesion was con-
fined to the striatum, laterally and dorsally bordered by
the corpus callosum and ventrally by the anterior commis-
sure. The lesioned area in the striatum stretched along
a length of approximately 4 mm, starting rostrally at
Bregma 1.6 up to Bregma -2.2 [15]. The area affected
by the ischaemia comprised a mean volume of 92 mm3
(28). In the BMSC-treated rats too, the lesioned area was
restricted to the striatum (Figure 2). Here too, the lesioned
area lacked NeuN-positive viable neurons and was packed
with activated Iba-1-positive microglia; no difference in
microglia density could be detected between the BMSC-
treated rats and the saline-treated ones. The size of the
lesion in the BM-treated rats was significantly reduced to
40 mm3 (18) (Figure 2c). Surprisingly, analysis of the
presence of transplanted BMSCs 2 weeks after MCAO and
BMSC treatment revealed only very sporadic mini-Ruby-
labelled BMSCs in and around the lesion site, in the paren-
chyma and in blood vessels (Figure 2d). None of these
labelled cells showed the expression of a marker for neural
cell types. Only the spleen, but not lung or liver tissue,
contained a few mini-Ruby-labelled BMSCs after 2 weeks.
Early kinetics of BM cells in ischaemic lesions
As very few of the implanted BMSCs could be found in or
around the striatal ischaemic lesion at 2 weeks after
implantation, we investigated the fate and kinetics of
BMSCs in the first 24 h after arterial administration in
correlation to the development of the ischaemic lesion in
the striatum as a consequence of MCAO. To that purpose,
we fixed MCAO rats at 3, 6, 12 and 24 h after BMSC
administration.
Development of striatal ischaemic lesion Analysis of sec-
tions of the striatum stained with cresyl-violet for a
general overview showed that most of the tissue disrup-
tion and necrosis in the striatum developed between 12
and 24 h after BMSC administration (Figure 3). The first
apoptotic neurons inside the ischaemic lesion, as indicated
by activated caspase-3 immunostaining, could be detected
at 12 h (Figure 3e,f). However, the first indication for the
onset of local striatal cell damage was provided by the first
appearance of activated microglia in the striatum at 6 h.
At 24 h, clear accumulation of activated microglia could
be detected in the lesioned striatum (Figure 4). The
described pattern of lesion formation in the striatum and
microglia accumulation/activation was seen in BMSC-
treated rats as well as in saline-treated animals.
Fate of implanted BMSCs BMSCs were administered 2 h
after the onset of MCAO, that is, during the development of
the ischaemic lesion. To determine the fate of the majority
of the implanted BMSCs after arterial administration, we
have examined filtering peripheral organs, such as lungs,
liver and spleen, at the four time points: already at 3 h
after BMSC administration, rhodamine–dextran-positive
and CD45/CD34-positive BMSCs could be detected in fol-
licle centres within the spleen (Figure 5). Only sparsely
injected BMSCs were observed in the other tissues. The
number of grafted cells that could be detected in the spleen
during the time period studied, that is, up to 24 h after
implantation, was counted in randomly chosen sections
along the length of the spleen. At 12 h, on average 16
cells were found per spleen section, accounting in the total
spleen for approximately 9.65 ¥ 105, that is, >95% of the
number of BMSCs implanted.
Although labelled BMSCs could be detected in the brain
at 3 h after BMSC administration inside blood vessels
(Figure 6a,b), the first BMSCs that were observed within
the striatal tissue in and around the lesion site appeared
at 6 h after implantation, concomitant with the appear-
ance of activated microglia (Figure 6c). Their number
increased at 12 h after implantation. Most of the grafted
BMSCs were located in and around the lesioned area in
close vicinity of activated microglia. At 24 h, some of
these microglia showed phagocytotic activity and con-
tained rhodamine–dextran inclusions (Figure 6f). The
number of labelled BMSCs in and around the striatum
Figure 2. Ischaemic lesion in striatum 2 weeks after middle cerebral artery occlusion (MCAO) in bone marrow stem cell (BMSC)-treated and
saline-treated rats. (a,a’) Iba-1 immunostaining (brown) of activated microglia reveals the size of the lesion in the left side of the striatum of
saline-treated rats (magnification in a’). (b,b’) Rats that received an intra-arterial injection of BMSCs 1 h after MCAO show a smaller lesion
size as delineated by Iba-1 microglia (magnification in b’). (c) Measurement of the lesion sizes in saline-treated and BMSC-treated rats show a
large reduction in lesion size in the BMSC-treated animals in comparison with the saline-treated rats. (d’) Only sporadically could a
mini-Ruby-labelled transplanted BMSC (arrow) be detected in the lesioned striatum 2 weeks after MCAO and BMSC injection (bv, blood
vessel; cor, cortex; cc, corpus callosum; str, striatum). Bars in a and b, 0.5 mm; in a’, b’ and d, 100 mm.
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Figure 3. Overview of striatum during the first 24 h after middle cerebral artery occlusion (MCAO) and bone marrow stem cell (BMSC)
implantation. (a–d) Cresyl-violet staining of striatal sections reveals the appearance of structural damage in the striatum at 12 h after
MCAO and BMSC implantation; the lesioned area (arrow) is most clear in a section taken at 24 h after MCAO and BMSC injection.
(e–h) Immunostaining for activated caspase-3 (brown) in sections taken from the MCAO-affected striatum shows the appearance of
apoptotic cells (arrowheads) at 12 h after MCAO and BMSC injection; the number of apoptotic cells increased during the next 12 h
(h, arrowheads). Bars in a–d, 1 mm; in e–h, 100 mm.
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Figure 4. At 24 h after middle cerebral artery occlusion and bone marrow stem cell injection, accumulation of activated, Iba-1-positive
microglia were observed at the lesioned striatum (a; detail in a’); the contralateral striatum contained an even-distributed population of
quiescent microglia (b; detail in b’). Bars in a and b, 100 mm; a’ and b’, 50 mm.
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6 h 12 h
24 h 24 h
3 h
Figure 5. Grafted bone marrow stem cells (BMSCs) in spleen. (a) Mini-Ruby (red-fluorescent) and (a’) CD45 (green-fluorescent)
double-labelled BMSCs could be detected in follicles in the spleen already at 3 h after intra-arterial administration. (b–d) Their number
gradually increased during the first 24 h after injection (d’, detail of 24-h spleen follicle). At 12 h, on average 16 cells were found per spleen
section, accounting in the total spleen for >95% of the implanted cells; blue, Hoechst nuclear staining. Bars a–d, 0.5 mm; d’, 50 mm.
98 E. Keimpema et al.
© 2009 Blackwell Publishing Ltd, Neuropathology and Applied Neurobiology, 35, 89–102
lesion found at 24 h after implantation was slightly lower
than at 12 h (Figure 6e).
Discussion
Intra-arterial injection of syngeneic BMSCs 2 h after the
onset of MCAO leads to a significant reduction to approxi-
mately 50% of the ischaemic lesion. However, histological
evaluation 2 weeks later could not demonstrate the pres-
ence of implanted BMSCs in or around the lesion site.
Analysis of the early kinetics of BMSCs during the first
24 h after injection revealed that starting from 6 h after
MCAO, concomitant with the appearance of activated
microglia, a small number of BMSCs temporarily invaded
the lesion site. The vast majority of implanted cells,
however, appeared to be trapped in the spleen.
Our findings regarding the reduction of the lesion size
are in line with the data of Iihoshi et al. [12]. They showed
a clear correlation between lesion size and the time point
of intravenous stem cell administration: whereas an acute
injection 3 h after MCAO induction almost annihilated
lesion formation, later administration resulted in a propor-
tionally less reduced ischaemic lesion size [12]. We admin-
istered the BMSCs even earlier, at 2 h after ischaemia
onset and, although this did lead to a significant lesion
reduction, it was not as prominent as shown by Iihoshi
and co-workers [12]. Apparently, earlier intravascular
administration of BMSCs is suboptimal and it can be
argued that at an earlier time point, that is, during a very
early stage of lesion formation, signals that attract the
BMSCs towards the lesion are still too low and inefficient
and so most of the implanted BMSCs became trapped
into the spleen. Two weeks after administration, we were
unable to detect implanted BMSCs in the lesioned stria-
tum. Obviously, we may have missed unlabelled BMSCs
but, to limit this possibility, we had chosen to use a
rhodamine–dextran conjugate to label our BMSCs. This
type of labelling is easy, far more efficient (>98%) and less
stressful for cells than most other labelling strategies. The
intracellular presence of rhodamine–dextran conjugates
can be detected for up to 6 months and it is presently used
in combination with gadolinium as a superior novel con-
trast agent and fluorescent marker to track implanted
stem cells both by magnetic resonance imaging and fluo-
rescence microscopy [16,17].
The absence of implanted BMSCs 2 weeks after MCAO
and intravascular injection in the striatum seems to
exclude the possibility that neural cell replacement in the
striatum by BMSCs accounts for the significant ischaemic
lesion size reduction observed. Apparently, the early
transient presence of an, although small, number of
implanted BMSC in the early phase of lesion formation
caused a reduction in ischaemic lesion size. Potential
players in that mechanism may be activated microglia.
Reactive microgliosis after MCAO is characterized by a ste-
reotypical graded response, including microglial activa-
tion, expansion and migration. In both saline-treated and
BMSC-treated rats, we were able to detect the massive
accumulation of activated microglia in the lesioned
striatum 2 weeks after MCAO. Although this microglial
response has been considered to contribute to neuronal
damage [18–20], a growing line of evidence suggests a
neuroprotective role for microglia and their neuroimmune
agents in various neuropathological conditions [21,22],
among which are ischaemic injury and oxygen-glucose
deprivation [23–26]. Recently, Lalancette-Hebert et al.
[27] demonstrated that ablation of proliferating micro-
glial cells exacerbated ischaemic injury in the brain. The
neuroprotective potential of the microglia appeared to be
mediated by the secretion of neurotrophic and anti-
apoptotic molecules, such as IGF-1[27]. A similar neuro-
protective neurogenic response of microglia mediated by
IGF-1 appears to be triggered by specific cytokines [28];
some of these cytokines have been shown to be produced
by BMSCs. Although the number of implanted BMSCs at
the lesion site was very small and transient, they may have
effectively and temporarily instructed activated microglia
to a stronger neuroprotective anti-apoptotic response,
resulting in a smaller ischaemic lesion. However, so far,
immunohistochemical analyses (IGF-1, TGFb, BDNF, IL-4,
IL-10 and IFN-y) by us to identify a different activation
response of microglia by the implanted BMSCs remained
inconclusive (data not shown). Besides the microglia,
implanted BMSCs themselves have been shown to secrete
active agents, such as VEGF, bFGF and BDNF, which may
promote angio-genesis and neurogenesis [8–10] and so
contribute to lesion size reduction.
In conclusion, we have shown that the transient pres-
ence of a small number of intra-arterially administered
BMSCs at an early stage of ischaemic injury can signifi-
cantly reduce the ultimate lesion size.
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Figure 6. Grafted bone marrow stem cells (BMSCs) in the brain. (a) At 3 h after injection, rhodamine–dextran-labelled BMSCs could be
detected in a few large bloodvessels; (b,b’) most of these cells were co-immunostained for CD45. (c,c’) At 6 h, only sporadically could a
red-fluorescent bone marrow stem cell (c’, CD45-positive) be detected in the lesioned striatum. At 12 (d) and 24 h (f; indicated area
magnified in f ’), an increase in the number of rhodamine–dextran-labelled BMSCs could be detected in the lesioned striatum. In some
sections, activated Iba-1-positive (green) microglia contacted the grafted BMSCs and some of them contained rhodamine–dextran inclusions
(arrows in f ’). Blue, Hoechst nuclear staining; red, rhodamine–dextran; green, Iba-1. (e) Quantification of the number of grafted BMSCs
present in the lesioned striatum at 3, 6, 12 and 24 h and 2 weeks after intra-arterial implantation. Bars indicate the mean number of
rhodamine–dextran-labelled BMSCs (standard deviation) per section of lesioned striatum, determined in three rats. Bars in a, 100 mm; in
b–f: 50 mm; in f ’, 20 mm.
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